Development Status
For information about the science behind the creation of EVade™ RNase QBI-139 click here.
In Spetember 2006, QBI-139 was selected as the
lead candidate. Large scale production began in early 2007,
and toxicology studies have been completed. The Company is on
target to submit an Investigational New Drug Application in
the first half of 2008, which would allow a Phase 1 clinical
trial to begin soon after.
In selecting the lead candidate, over thirty EVade™
RNases were manufactured and tested in vivo against
a variety of cancers. QBI-139 was selected because of its broad
efficacy and excellent safety profile. QBI-139 causes significant
tumor growth inhibition in pancreatic, prostate, non-small cell
lung, and ovarian cancers. |
